Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Clinical Therapeutics of Non-small Cell Lung Cancer
share announcement

Clinical Therapeutics of Non-small Cell Lung Cancer

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pulmonology".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 10779

Special Issue Editors

Dr. Hiroaki Kuroda

E-Mail Website
Guest Editor
Aichi Cancer Center Hospital, Nagoya, Japan
Interests: thoracic surgery; lung cancer; non-small cell lung cancer
Dr. Katsuhiro Masago

E-Mail Website
Guest Editor
Aichi Cancer Center Hospital, Nagoya, Japan
Interests: pathology and molecular diagnosis
Prof. Dr. Hirokazu Matsushita

E-Mail Website
Guest Editor
Aichi Cancer Center Research Institute, Nagoya, Japan
Interests: translational research; immunology

Special Issue Information

Dear Colleagues,

The recent development of less-invasive surgical techniques such as video-assisted, robot-assisted, and port-reduced thoracic surgery for non-small-cell lung cancer (NSCLC) has made remarkable progress in efficacy and safety. Targeted therapies for metastatic or advanced NSCLCs have also shown remarkable development. Recent guideline-consistent recommendations are to check for driver gene mutations or PD-L1 status for those NSCLCs. As for the perioperative treatment of NSCLC, molecular targeted medicine and immune-checkpoint inhibitors are to be considered instead of conventional chemotherapy and chemoradiotherapy. For example, in the ADAURA clinical trial (NCT02511106), adjuvant osimertinib conferred a significant survival benefit in patients with IB to IIIA EGFR-mutation-positive NSCLC. Therefore, the application of these targeted drugs to earlier stages with completely resectable NSCLCs might confer a surprising survival benefit. 

The theme of this Special Issue is “how can the analysis of the cancer microenvironment be made feasible for an operation?”. Therefore, the focus of this Special Issue will be current outcomes or featured topics concerning the surgical treatment of NSCLCs in conjunction with analyses of cancer microenvironments. 

Dr. Hiroaki Kuroda
Dr. Katsuhiro Masago
Prof. Dr. Hirokazu Matsushita
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thoracic surgery
  • lung cancer
  • non-small cell lung cancer
  • surgery
  • molecule
  • immune therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 1773 KiB  
Article
Comparison between Fluorimetry (Qubit) and Spectrophotometry (NanoDrop) in the Quantification of DNA and RNA Extracted from Frozen and FFPE Tissues from Lung Cancer Patients: A Real-World Use of Genomic Tests
by Katsuhiro Masago, Shiro Fujita, Yuko Oya, Yusuke Takahashi, Hirokazu Matsushita, Eiichi Sasaki and Hiroaki Kuroda
Medicina 2021, 57(12), 1375; https://doi.org/10.3390/medicina57121375 - 17 Dec 2021
Cited by 22 | Viewed by 7961
Abstract
Background and Objectives: Panel-based next-generation sequencing (NGS) has been carried out in daily clinical settings for the diagnosis and treatment guidance of patients with non-small cell lung cancer (NSCLC). The success of genomic tests including NGS depends in large part on preparing better-quality [...] Read more.
Background and Objectives: Panel-based next-generation sequencing (NGS) has been carried out in daily clinical settings for the diagnosis and treatment guidance of patients with non-small cell lung cancer (NSCLC). The success of genomic tests including NGS depends in large part on preparing better-quality DNA or RNA; however, there are no established operating methods for preparing genomic DNA and RNA samples. Materials and Methods: We compared the following two quantitative methods, the QubitTM and NanoDropTM, using 585 surgical specimens, 278 biopsy specimens, and 82 cell block specimens of lung cancer that were used for genetic tests, including NGS. We analyzed the success rate of the genomic tests, including NGS, which were performed with DNA and RNA with concentrations that were outliers for the Qubit Fluorometer. Results: The absolute value for DNA concentrations had a tendency to be higher when measured with NanoDropTM regardless of the type of specimen; however, this was not the case for RNA. The success rate of DNA-based genomic tests using specimens with a concentration below the lower limit of QubitTM detection was as high as approximately 96%. At less than 60%, the success rate of RNA-based genomic tests, including RT-PCR, was not as satisfactory. The success rates of the AmpliSeqTM DNA panel sequencing and RNA panel sequencing were 77.8% and 91.5%, respectively. If at least one PCR amplification product could be obtained, then all RNA-based sequencing was performed successfully. Conclusions: The concentration measurements with NanoDropTM are reliable. The success rate of NGS with samples at concentrations below the limit of detection of QubitTM was relatively higher than expected, and it is worth performing PCR-based panel sequencing, especially in cases where re-biopsy cannot be performed. Full article
(This article belongs to the Special Issue Clinical Therapeutics of Non-small Cell Lung Cancer)
►▼ Show Figures

Figure 1

11 pages, 2570 KiB  
Article
Permissible Outcomes of Lobe-Specific Lymph Node Dissection for Elevated Carcinoembryonic Antigen in Non-Small Cell Lung Cancer
by Hiroaki Kuroda, Junji Ichinose, Katsuhiro Masago, Yusuke Takahashi, Takeo Nakada, Masayuki Nakao, Sakae Okumura, Kohei Hashimoto, Yosuke Matsuura, Noriaki Sakakura, Hirokazu Matsushita and Mingyon Mun
Medicina 2021, 57(12), 1365; https://doi.org/10.3390/medicina57121365 - 14 Dec 2021
Cited by 4 | Viewed by 2392
Abstract
Background and Objectives: Lobe-specific nodal dissection (L-SND) is currently acceptable for the dissection of early-stage non-small cell lung cancer (NSCLC) but not for cancers of more advanced clinical stages. We aimed to assess the efficacy of L-SND, compared to systemic nodal dissection [...] Read more.
Background and Objectives: Lobe-specific nodal dissection (L-SND) is currently acceptable for the dissection of early-stage non-small cell lung cancer (NSCLC) but not for cancers of more advanced clinical stages. We aimed to assess the efficacy of L-SND, compared to systemic nodal dissection (SND). Materials and Methods: We retrospectively collected the clinical data of patients with carcinoembryonic antigen (CEA) abnormality who underwent complete resection of NSCLC via lobectomy or more in addition to either SND or L-SND at two cancer-specific institutions from January 2006 to December 2017. Results: A total of 799 patients, including 265 patients who underwent SND and 534 patients who underwent L-SND, were included. On multivariate analysis, thoracotomy, more than lobectomy, cN1-2, advanced pathological stage, adjuvant treatment, and EGFR or ALK were strongly associated with SND. No significant differences were found in overall survival, disease-free survival, and overtime survival after propensity adjustment (p = 0.09, p = 0.11, and p = 0.50, respectively). There were no significant differences in local (p = 0.16), regional (p = 0.72), or distant (p = 0.39) tumor recurrence between the two groups. Conclusions: SND did not improve the prognosis of NSCLC patients with CEA abnormality. Complete pulmonary resection via L-SND seems useful for NSCLC patients with CEA abnormality. Full article
(This article belongs to the Special Issue Clinical Therapeutics of Non-small Cell Lung Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop